Published in J Nanobiotechnology on May 08, 2007
Targeted hyperthermia using metal nanoparticles. Adv Drug Deliv Rev (2009) 2.12
Building bridges between Ayurveda and Modern Science. Int J Ayurveda Res (2010) 1.92
Noble metal nanoparticles applications in cancer. J Drug Deliv (2011) 1.66
Intracellular gold nanoparticles enhance non-invasive radiofrequency thermal destruction of human gastrointestinal cancer cells. J Nanobiotechnology (2008) 1.56
Intrinsic therapeutic applications of noble metal nanoparticles: past, present and future. Chem Soc Rev (2012) 1.55
Fabrication of gold nanoparticles for targeted therapy in pancreatic cancer. Adv Drug Deliv Rev (2009) 1.54
Gold nanoparticles: a revival in precious metal administration to patients. Nano Lett (2011) 1.47
Gold nanoparticles: preparation, properties, and applications in bionanotechnology. Nanoscale (2011) 1.32
Inorganic nanoparticles in cancer therapy. Pharm Res (2010) 1.11
Visualization of interaction between inorganic nanoparticles and bacteria or fungi. Int J Nanomedicine (2010) 1.10
Nanobiotechnology today: focus on nanoparticles. J Nanobiotechnology (2007) 0.95
A review on gold nanoparticles radiosensitization effect in radiation therapy of cancer. Rep Pract Oncol Radiother (2010) 0.94
Functionalized Gold Nanoparticles and Their Biomedical Applications. Nanomaterials (Basel) (2011) 0.90
Fabrication and functional characterization of goldnanoconjugates for potential application in ovarian cancer. J Mater Chem (2010) 0.90
Gold and silver nanoparticles from Trianthema decandra: synthesis, characterization, and antimicrobial properties. Int J Nanomedicine (2012) 0.90
Tuning pharmacokinetics and biodistribution of a targeted drug delivery system through incorporation of a passive targeting component. Sci Rep (2014) 0.84
Inhibiting the growth of pancreatic adenocarcinoma in vitro and in vivo through targeted treatment with designer gold nanotherapeutics. PLoS One (2013) 0.80
Surface plasmon resonance-induced photoactivation of gold nanoparticles as bactericidal agents against methicillin-resistant Staphylococcus aureus. Int J Nanomedicine (2014) 0.80
Anthelmintic efficacy of gold nanoparticles derived from a phytopathogenic fungus, Nigrospora oryzae. PLoS One (2014) 0.79
Gold nanoparticles as physiological markers of urine internalization into urothelial cells in vivo. Int J Nanomedicine (2013) 0.78
The role of nanomedicine in cell based therapeutics in cancer and inflammation. Int J Mol Cell Med (2012) 0.77
Systemically administered collagen-targeted gold nanoparticles bind to arterial injury following vascular interventions. Physiol Rep (2017) 0.75
A core-shell nanomaterial with endogenous therapeutic and diagnostic functions. Cancer Nanotechnol (2010) 0.75
Nanotechnology applications in hematological malignancies (Review). Oncol Rep (2015) 0.75
Targeted Intracellular Heat Transfer in Cancer Therapy: Assessment of Asparagine-laminated Gold Nanoparticles in Cell Model of T cell Leukemia. Iran J Public Health (2017) 0.75
Gadolinium-Doped Gallic Acid-Zinc/Aluminium-Layered Double Hydroxide/Gold Theranostic Nanoparticles for a Bimodal Magnetic Resonance Imaging and Drug Delivery System. Nanomaterials (Basel) (2017) 0.75
Gold nanoparticles: assembly, supramolecular chemistry, quantum-size-related properties, and applications toward biology, catalysis, and nanotechnology. Chem Rev (2004) 13.49
National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood (1996) 13.35
Nanoshell-mediated near-infrared thermal therapy of tumors under magnetic resonance guidance. Proc Natl Acad Sci U S A (2003) 12.17
Self-assembled monolayers of thiolates on metals as a form of nanotechnology. Chem Rev (2005) 10.41
Gold nanoparticles: a new X-ray contrast agent. Br J Radiol (2006) 6.31
Surface plasmon resonance scattering and absorption of anti-EGFR antibody conjugated gold nanoparticles in cancer diagnostics: applications in oral cancer. Nano Lett (2005) 4.70
An immunocolloid method for the electron microscope. Immunochemistry (1971) 4.61
Selective laser photo-thermal therapy of epithelial carcinoma using anti-EGFR antibody conjugated gold nanoparticles. Cancer Lett (2005) 4.19
Toxicity of gold nanoparticles functionalized with cationic and anionic side chains. Bioconjug Chem (2004) 3.52
Selective cell targeting with light-absorbing microparticles and nanoparticles. Biophys J (2003) 3.49
Angiogenesis and apoptosis. Semin Cancer Biol (2003) 2.86
Gastrointestinal persorption and tissue distribution of differently sized colloidal gold nanoparticles. J Pharm Sci (2001) 2.09
Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice. Cancer Res (2000) 2.07
Antiangiogenic properties of gold nanoparticles. Clin Cancer Res (2005) 1.78
VEGF receptors on chronic lymphocytic leukemia (CLL) B cells interact with STAT 1 and 3: implication for apoptosis resistance. Leukemia (2005) 1.46
Analgesic activity of gold preparations used in Ayurveda & Unani-Tibb. Indian J Med Res (1998) 1.19
The clinical and biologic importance of neovascularization and angiogenic signaling pathways in chronic lymphocytic leukemia. Semin Oncol (2006) 1.07
Adaphostin-induced apoptosis in CLL B cells is associated with induction of oxidative stress and exhibits synergy with fludarabine. Blood (2004) 1.06
Synthesis and properties of water-soluble gold colloids covalently derivatized with neutral polymer monolayers. J Am Chem Soc (2002) 0.96
Tracing uptake of C3dg-conjugated antigen into B cells via complement receptor type 2 (CR2, CD21). Blood (2000) 0.91
Vascular endothelial growth factor signaling pathway as an emerging target in hematologic malignancies. Oncologist (2001) 0.91
Cell adhesion peptide modification of gold-coated polyurethanes for vascular endothelial cell adhesion. J Biomed Mater Res (2001) 0.90
Monoclonal antibody therapy of chronic lymphocytic leukemia. Cancer Immunol Immunother (2005) 0.89
The angiogenic status of B-CLL B cells: role of the VEGF receptors. Leuk Res (2004) 0.83
Angiogenesis in hematologic malignancies. Ann Hematol (2002) 0.81
Effect of gold on survival of tumor-bearing mice. Cancer Biother Radiopharm (1998) 0.80
Antitumor effect of gold as revealed by growth suppression of cultured cancer cells. Cancer Biother Radiopharm (1998) 0.79
International network of cancer genome projects. Nature (2010) 20.35
Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature (2012) 8.31
ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med (2004) 7.04
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med (2014) 6.73
Association of a microRNA/TP53 feedback circuitry with pathogenesis and outcome of B-cell chronic lymphocytic leukemia. JAMA (2011) 3.16
Prospective evaluation of clonal evolution during long-term follow-up of patients with untreated early-stage chronic lymphocytic leukemia. J Clin Oncol (2006) 3.06
Chromosome anomalies detected by interphase fluorescence in situ hybridization: correlation with significant biological features of B-cell chronic lymphocytic leukaemia. Br J Haematol (2003) 2.72
Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia. Blood (2008) 2.72
Genome-wide association study of follicular lymphoma identifies a risk locus at 6p21.32. Nat Genet (2010) 2.37
Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia. J Clin Oncol (2012) 2.36
Genetic variation in 1253 immune and inflammation genes and risk of non-Hodgkin lymphoma. Blood (2007) 2.31
CD49d expression is an independent predictor of overall survival in patients with chronic lymphocytic leukaemia: a prognostic parameter with therapeutic potential. Br J Haematol (2008) 2.29
Targeted delivery of gemcitabine to pancreatic adenocarcinoma using cetuximab as a targeting agent. Cancer Res (2008) 2.20
B-cell count and survival: differentiating chronic lymphocytic leukemia from monoclonal B-cell lymphocytosis based on clinical outcome. Blood (2008) 2.18
Operative management of sacral chordoma. J Bone Joint Surg Am (2005) 2.12
Direct evidence for endothelial vascular endothelial growth factor receptor-1 function in nitric oxide-mediated angiogenesis. Circ Res (2006) 2.12
Neuropilin-1 promotes cirrhosis of the rodent and human liver by enhancing PDGF/TGF-beta signaling in hepatic stellate cells. J Clin Invest (2010) 2.06
Nanoconjugation modulates the trafficking and mechanism of antibody induced receptor endocytosis. Proc Natl Acad Sci U S A (2010) 1.95
Methylprednisolone-rituximab is an effective salvage therapy for patients with relapsed chronic lymphocytic leukemia including those with unfavorable cytogenetic features. Leuk Lymphoma (2007) 1.92
Tissue engineering of bone: material and matrix considerations. J Bone Joint Surg Am (2008) 1.91
Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B chronic lymphocytic leukemia. Blood (2013) 1.87
Effect of local sequential VEGF and BMP-2 delivery on ectopic and orthotopic bone regeneration. Biomaterials (2009) 1.87
Genome-wide association study identifies multiple risk loci for chronic lymphocytic leukemia. Nat Genet (2013) 1.85
Vitamin D insufficiency and prognosis in chronic lymphocytic leukemia. Blood (2010) 1.83
Simvastatin reduces venous stenosis formation in a murine hemodialysis vascular access model. Kidney Int (2013) 1.83
Neuropilin-1-mediated vascular permeability factor/vascular endothelial growth factor-dependent endothelial cell migration. J Biol Chem (2003) 1.82
The use of microorganisms for the formation of metal nanoparticles and their application. Appl Microbiol Biotechnol (2005) 1.81
LEF-1 is a prosurvival factor in chronic lymphocytic leukemia and is expressed in the preleukemic state of monoclonal B-cell lymphocytosis. Blood (2010) 1.80
Biological and prognostic significance of interphase fluorescence in situ hybridization detection of chromosome 13 abnormalities (delta13) in multiple myeloma: an eastern cooperative oncology group study. Cancer Res (2002) 1.79
Genome-wide association study identifies a novel susceptibility locus at 6p21.3 among familial CLL. Blood (2010) 1.79
Antiangiogenic properties of gold nanoparticles. Clin Cancer Res (2005) 1.78
COL1 C-propeptide cleavage site mutations cause high bone mass osteogenesis imperfecta. Hum Mutat (2011) 1.77
Effect of nanoparticle surface charge at the plasma membrane and beyond. Nano Lett (2010) 1.77
Anthropometric characteristics, physical activity, and risk of non-Hodgkin's lymphoma subtypes and B-cell chronic lymphocytic leukemia: a prospective study. Am J Epidemiol (2002) 1.76
De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: the M. D. Anderson and Mayo Clinic experience. Blood (2009) 1.75
Phase I clinical trial of CpG oligonucleotide 7909 (PF-03512676) in patients with previously treated chronic lymphocytic leukemia. Leuk Lymphoma (2011) 1.71
Aberrant expression of B-lymphocyte stimulator by B chronic lymphocytic leukemia cells: a mechanism for survival. Blood (2002) 1.70
Multiple-channel scaffolds to promote spinal cord axon regeneration. Biomaterials (2005) 1.68
Nitric oxide promotes endothelial cell survival signaling through S-nitrosylation and activation of dynamin-2. J Cell Sci (2007) 1.66
Proinflammatory functions of vascular endothelial growth factor in alloimmunity. J Clin Invest (2003) 1.66
Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients. Blood (2002) 1.63
Myogenic Akt signaling regulates blood vessel recruitment during myofiber growth. Mol Cell Biol (2002) 1.63
Circulating microvesicles in B-cell chronic lymphocytic leukemia can stimulate marrow stromal cells: implications for disease progression. Blood (2009) 1.61
Addition of granulocyte macrophage colony stimulating factor does not improve response to early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximab. Leuk Lymphoma (2012) 1.61
Prognosis at diagnosis: integrating molecular biologic insights into clinical practice for patients with CLL. Blood (2003) 1.60
Identification of a global gene expression signature of B-chronic lymphocytic leukemia. Mol Cancer Res (2003) 1.60
Retention of in vitro and in vivo BMP-2 bioactivities in sustained delivery vehicles for bone tissue engineering. Biomaterials (2008) 1.59
Noninvasive radiofrequency field-induced hyperthermic cytotoxicity in human cancer cells using cetuximab-targeted gold nanoparticles. J Exp Ther Oncol (2008) 1.59
Mesenchymal stem cells for bone repair and metabolic bone diseases. Mayo Clin Proc (2009) 1.59
GWAS of follicular lymphoma reveals allelic heterogeneity at 6p21.32 and suggests shared genetic susceptibility with diffuse large B-cell lymphoma. PLoS Genet (2011) 1.58
Intracellular gold nanoparticles enhance non-invasive radiofrequency thermal destruction of human gastrointestinal cancer cells. J Nanobiotechnology (2008) 1.56
Quantitative DNA methylation analysis identifies a single CpG dinucleotide important for ZAP-70 expression and predictive of prognosis in chronic lymphocytic leukemia. J Clin Oncol (2012) 1.56
Endothelial cell-specific chemotaxis receptor (ecscr) promotes angioblast migration during vasculogenesis and enhances VEGF receptor sensitivity. Blood (2010) 1.55
Intrinsic therapeutic applications of noble metal nanoparticles: past, present and future. Chem Soc Rev (2012) 1.55
New insights into pancreatic cancer-induced paraneoplastic diabetes. Nat Rev Gastroenterol Hepatol (2013) 1.54
Fabrication of gold nanoparticles for targeted therapy in pancreatic cancer. Adv Drug Deliv Rev (2009) 1.54
Modulating pharmacokinetics, tumor uptake and biodistribution by engineered nanoparticles. PLoS One (2011) 1.53
Revealing the role of phospholipase Cβ3 in the regulation of VEGF-induced vascular permeability. Blood (2012) 1.51
Percentage of smudge cells on routine blood smear predicts survival in chronic lymphocytic leukemia. J Clin Oncol (2009) 1.51
C terminus of RGS-GAIP-interacting protein conveys neuropilin-1-mediated signaling during angiogenesis. FASEB J (2006) 1.50
Chemically modified peptides targeting the PDZ domain of GIPC as a therapeutic approach for cancer. ACS Chem Biol (2012) 1.50
Treatment of autoimmune cytopenia complicating progressive chronic lymphocytic leukemia/small lymphocytic lymphoma with rituximab, cyclophosphamide, vincristine, and prednisone. Leuk Lymphoma (2010) 1.49
KDR stimulates endothelial cell migration through heterotrimeric G protein Gq/11-mediated activation of a small GTPase RhoA. J Biol Chem (2002) 1.49
Brief report: natural history of individuals with clinically recognized monoclonal B-cell lymphocytosis compared with patients with Rai 0 chronic lymphocytic leukemia. J Clin Oncol (2009) 1.48
Bioactive poly(L-lactic acid) conduits seeded with Schwann cells for peripheral nerve regeneration. Biomaterials (2002) 1.47
NHERF-2 maintains endothelial homeostasis. Blood (2012) 1.47
Vascular endothelial growth factor and semaphorin induce neuropilin-1 endocytosis via separate pathways. Circ Res (2008) 1.43
Computational identification of CDR3 sequence archetypes among immunoglobulin sequences in chronic lymphocytic leukemia. Leuk Res (2008) 1.42
Bone biopsy derived marrow stromal elements rescue chronic lymphocytic leukemia B-cells from spontaneous and drug induced cell death and facilitates an "angiogenic switch". Leuk Res (2007) 1.41
Designing ideal conduits for peripheral nerve repair. Neurosurg Focus (2009) 1.38
Pentostatin, cyclophosphamide, and rituximab regimen in older patients with chronic lymphocytic leukemia. Cancer (2007) 1.38
Inhibition of vessel permeability by TNP-470 and its polymer conjugate, caplostatin. Cancer Cell (2005) 1.37
Regulatory role of dynamin-2 in VEGFR-2/KDR-mediated endothelial signaling. FASEB J (2005) 1.37
Effect of insulin deprivation on muscle mitochondrial ATP production and gene transcript levels in type 1 diabetic subjects. Diabetes (2007) 1.36
Diffuse large B-cell lymphoma (Richter syndrome) in patients with chronic lymphocytic leukaemia (CLL): a cohort study of newly diagnosed patients. Br J Haematol (2013) 1.34
Adrenomedullin is up-regulated in patients with pancreatic cancer and causes insulin resistance in β cells and mice. Gastroenterology (2012) 1.34
Prognostic importance of T and NK-cells in a consecutive series of newly diagnosed patients with chronic lymphocytic leukaemia. Br J Haematol (2008) 1.33
Phase I trial of daily oral Polyphenon E in patients with asymptomatic Rai stage 0 to II chronic lymphocytic leukemia. J Clin Oncol (2009) 1.33
Gold nanoparticles: opportunities and challenges in nanomedicine. Expert Opin Drug Deliv (2010) 1.32
Risk factors for development of a second lymphoid malignancy in patients with chronic lymphocytic leukaemia. Br J Haematol (2007) 1.32
Snrk-1 is involved in multiple steps of angioblast development and acts via notch signaling pathway in artery-vein specification in vertebrates. Blood (2008) 1.32
Neuropilin-1 modulates p53/caspases axis to promote endothelial cell survival. PLoS One (2007) 1.32
Effect of rapamycin alone and in combination with antiangiogenesis therapy in an orthotopic model of human pancreatic cancer. Clin Cancer Res (2004) 1.31
How we treat Richter syndrome. Blood (2014) 1.31